 |
|
|
 |
 |
|
|
 |
 |
|
|
Adolph M. Hutter, Jr., MD
|
 |
|
|
William T. Abraham, MD
Steven B. Abramson, MD
Jeff Anderson, MD
Najib Ayas, MD, MPH
George L. Bakris, MD
Peter B. Berger, MD
Deepak L. Bhatt, MD
Henry Black, MD
Robert O. Bonow, MD
Eugene Braunwald, MD, MACC
Robert Califf, MD
Aram V. Chobanian, MD
Christopher P. Cannon, MD
Jay N. Cohn, MD
Jerome D. Cohen, MD
Marc Cohen, MD
David A. Cox, MD, FACC
Bruce Cronstein, MD
George D. Dangas, MD, FACC
Prakash Deedwania, MD
Richard Devereux, MD
Nabil El-Sherif, MD
Keith C. Ferdinand, MD
James J. Ferguson, MD
John M. Flack, MD, MPH
Gregg C. Fonarow, MD
Keith Fox, MB, ChB
Haralambos Gavras, MD
J. Michael Gaziano, MD, MPH
C. Michael Gibson, MS, MD, FACC
Thomas Giles, MD
Michael M. Givertz, MD
Nieca Goldberg, MD
Antonio M. Gotto, MD
Christopher B. Granger, MD
Cindy Grines, MD
Robert A. Harrington, MD
James Hoekstra, MD
James L. Januzzi , MD
Peter H. Jones, MD
Timothy Johnson, MD
Stevo Julius, MD
William B. Kannel, MD
Dean J. Kereiakes, MD
Michael Kim, MD
Allan L. Klein, MD
Marvin A. Konstam, MD
Peter Kowey, MD
John Laragh, MD
John C. LaRosa, MD
James de Lemos, MD
Glenn N. Levine, MD
Peter Libby, MD
Michael Lincoff, MD
Lars Lindholm, MD
Kenneth W. Mahaffey, MD
Alan S. Maisel, MD
Barry J. Materson, MD
Laura Mauri, MD
Mary Ann McLaughlin, MD
Jean McSweeney, PhD, RN
Franz H. Messerli, MD
David J. Moliterno, MD, FACC
Gilles Montalescot, MD
David A. Morrow, MD, FACC
Arthur J. Moss, MD
Debabrata Mukherjee, MD, FACC
Steven E. Nissen, MD
Christopher O'Donnell, MD
E. Magnus Ohman, MD, FRCPI, FACC
Michael O'Rourke, MD
William Franklin Peacock IV, MD, FACEP
Carl Pepine, MD
Marc Pfeffer, MD, PhD
Robert A. Phillips, MD, PhD
Thomas G. Pickering, MD
Bertram Pitt, MD
Jorge Plutzky, MD
Charles V. Pollack, Jr., MA, MD, FACEP
Dwight Robinson
Elijah Saunders, MD
Marc J. Semigran, MD
Benjamin M. Scirica, MD
Marc A. Silver, MD
Sidney C. Smith, Jr, MD
Scott D. Solomon, MD
Laurence Sperling, MD
Sarah A. Spinler, PharmD
Steven R. Steinhubl, MD
Lynne W. Stevenson, MD
Gregg W. Stone, MD,FACC
James E. Tcheng, MD
James Udelson, MD
Richard L. Verrier, PhD
Michael A. Weber, MD
Howard Weintraub, MD
Matt Weir, MD
Nanette Wenger, MD
Harvey D. White, MB
William White, MD
Howard Willens, MD
Malissa J. Wood, MD
|
|
|
 |
|
|
| Now Available As Podcasts |
|
|
Cardiovascular Risk in Post-Bariatric Surgical Patients (02/2008)
|
|
|
Moderator: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator) |
|
|
Participants: |
Mary Ann McLaughlin, MD, MPH, FACC
Howard Willens, MD, FACC
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
 |
| |
Enter your email to receive reminders before
each ACC Conversation
|
privacy policy
|
|
|
| |
 |
View All Conversations
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
Nanette Wenger, MD
Michael Kim, MD
Jeff Anderson, MD
|
| Abstract: |
|
The 2007 ACC/AHA guidelines for the management of unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI) provide recommendations for the evaluation and management of patients with suspected UA/NSTEMI, based on recent clinical data. Join Dr. Dolph Hutter and his guests Dr. Jeffrey Anderson, Michael Kim, MD and Nanette Wenger, MD, for a discussion of the new guidelines.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
George D. Dangas, M.D., PhD
C. Michael Gibson M.S., M.D., F.A.C.C.
Gregg W. Stone, MD, FACC,
|
| Abstract: |
|
The recent ACC/AHA guidelines on unstable angina/non-ST-elevation myocardial infarction (UA/NSTEMI) include new roles for the direct thrombin inhibitors. In this program, Dr. Dolph Hutter moderates a discussion of the new guidelines with an expert panel including Drs. George Dangas, C. Michael Gibson and Gregg Stone.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
Mary Ann McLaughlin, MD, MPH, FACC
Howard P. Willens, MD, FACC
|
| Abstract: |
|
Bariatric surgery has evolved as a method of attaining significant weight loss in severely obese patients, resulting in substantial cardiovascular health benefits. In association with significant weight loss, the surgery also can result in a significant improvement or complete resolution of comorbidities such as dyslipidemia, hypertension, and diabetes mellitus.
In this conversation, Dr. Dolph Hutter discusses the cardiovascular effects of bariatric surgery and also patient selection criteria with Dr. Mary Ann McLaughlin of the Mount Sinai School of Medicine in New York, New York, and Dr. Howard Willens of the University of Miami Miller School of Medicine in Miami, Florida.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
James A. De Lemos, MD
Howard Willens, MD, FACC
|
| Abstract: |
|
Weight loss, in combination with treatment for of associated comorbidities, significantly reduces the risk of adverse cardiovascular events in obese patients.
In this conversation, Dr. Dolph Hutter discusses weight loss strategies and the clinical impact of significant weigh loss in obese patients with Dr. James de Lemos of the University of Texas, Southwestern Medical School in Dallas, Texas and Dr. Howard Willens, of the University of Miami Miller School of Medicine in Miami, Florida.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
Dr. Christopher Cannon, MD
Magnus Ohman, MD
|
| Abstract: |
|
Prior to invasive procedures, acute coronary syndrome (ACS) patients are best managed with antithrombotic agents. These agents decrease subsequent ischemic events, but also increase the risk of major bleeding.
The combination of bivalirudin, aspirin, and clopidogrel results in rates of ischemic events similar to standard treatments, but with significantly less bleeding. Dr. Christopher Cannon and Dr. Magnus Ohman join Dr. Adoph Hutter to discuss antithrombotic choices for ACS patients undergoing invasive procedures.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
Michael Gibson, MD
Laura Mauri, MD
|
| Abstract: |
|
Glycoprotein IIa/IIIb inhibitors (GPIs) improve outcomes following percutaneous coronary intervention (PCI) in patients with unstable angina, non-ST-elevated myocardial infarction (MI), and ST-elevated MI., but the optimal timing of pre-procedure administration remains to be determined.
In this conversation, Dr. Laura Mauri and Dr. Michael Gibson join Dr. Dolph Hutter to discuss the timing of IIb/IIIa inhibitor use in acute coronary syndrome (ACS) patients undergoing invasive procedures.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
Elliott Antman, MD
Marc Cohen, MD
|
| Abstract: |
|
New data from three ExTRACT-TIMI 25 analyses demonstrate that, in three different patient subgroups (percutaneous coronary intervention [PCI] within 30 days of randomization; clopidogrel or no clopidogrel; and in patients with renal dysfunction), enoxaparin improves outcome without, in most cases, significantly increasing the risk of bleeding.
In this ACC Conversation, Elliott Antman, MD, and Marc Cohen, MD, join Adolph Hutter, MD, to discuss these findings and their implications for clinical practice.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
Prakash Deedwania, MD
Gregg Fonarow, MD
|
| Abstract: |
|
Recent evidence demonstrates that the early, in-hospital initiation of high-dose statin therapy following an acute coronary syndrome (ACS) event reduces the risk of major cardiovascular disease (CVD) events and death. Long-term continuation of high-dose statins further reduces the risk of a recurrent event.
In this conversation, Dr. Prakash Deedwania and Dr. Gregg Fonarow join Dr. Adolf Hutter, Jr., to discuss the importance of initiating in-hospital high-dose statin therapy following ACS events.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
Michael Lincoff, MD
Cindy Grines, MD
Deepak Bhatt, MD
|
| Abstract: |
|
Consensus guidelines recommend that patients with drug-eluting stents (DES) should receive dual-antiplatelet therapy for at least 12 months following the stenting procedure. Experts contend that the benefits of dual-antiplatelet therapy outweigh the risk of bleeding in DES patients and that in some high-risk patients, therapy may need to be continued indefinitely.
In this conversationDr. A. Michael Lincoff, Dr. Deepak Bhatt, and Dr. Cindy Grines, join host Dr. Adolph M. Hutter, Jr. to discuss the prevention of late-thrombosis of drug-eluting stents.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
Prakash Deedwania, MD
Antonio M. Gotto, MD
|
| Abstract: |
|
In healthy patients, the ideal LDL-C target is <100 mg/dL; however, in high-risk patients, such as those with diabetes, metabolic syndrome, or cardiovascular disease, more aggressive control is needed to reach a target LDL-C less than 70 mg/dL. In high-risk individuals, maximal-dose statin therapy, combined with diet and exercise, or combination therapy if needed, can help clinicians achieve target LDL-C goals.
In this conversation, two diabetes experts Dr. Prakash Deedwania and Dr. Antonio Gotto, join Dr. Dolph Hutter to discuss methods for achieving target LDL cholesterol (LDL-C) levels.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
Steven E. Nissen, MD
Marc Pfeffer, PhD, FACC
Timothy Johnson, MD
|
| Abstract: |
|
A recent meta-analysis, published in The New England Journal of Medicine, has generated concern about rosiglitazone's cardiovascular effects. This article has received a great deal of media attention, and has sparked debate among both scientists and policy makers.
In this conversation, Dr. Timothy Johnson, Dr. Steve Nissen, and Dr. Marc Pfeffer join host Dr. Dolph Hutter to discuss the science at the heart of the debate, and the media's role in reporting on interpreting clinical articles.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter Jr, MD, MACC, FAHA, FESC (moderator)
Christopher P. Cannon, MD
John C. LaRosa, MD
|
| Abstract: |
|
The cardiovascular benefits of statins, whether at standard or intensive doses,
does not allow a simple way to sort out whether the benefits are due to the degree
of lowering of LDL-C or to some other effect of statins.Participating in this
conversation with Dr Dolph Hutter are Dr Christopher Cannon and Dr John LaRosa,
both expert cardiovascular disease specialists clinical trial investigators.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
J. Michael Gaziano, MD, MPH
Sidney C. Smith, Jr, MD
|
| Abstract: |
|
The Women's Health Study (WHS) is the largest trial of low-dose aspirin for the primary prevention of cardiovascular disease in women.
39,876 initially healthy women, 45 years of age or older were randomized to receive 100 mg of aspirin on alternate days or placebo. They were then monitored for 10 years for a first major cardiovascular event (i.e., nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes).
Two of the investigators from the WHS, Drs. Sidney Smith, Jr. and Michael Gaziano, discuss the study results, past relevant trial data, and how to effectively administer aspirin for primary and secondary prevention of cardiovascular diseases in various types of patients.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
Laurence Sperling, MD
|
| Abstract: |
|
Dr. Laurence Sperling is one of the authors of a recent review published in JACC evaluating several dietary approaches and the available scientific data relating to cardiovascular health. He discusses his paper and the well-known diets cardiologists are often asked about.
Watch as he describes the broad categories of diets and some of the specific features of the most popular ones.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
Zahi A. Fayad, PhD, Associate Professor of Radiology and Medicine, Mount Sinai School of Medicine
Yukihiko Momiyama, MD, Assistant Professor, First Department of Internal Medicine, National Defense Medical College, Japan
|
| Abstract: |
|
Thoracic aortic plaque regression after lipid-lowering therapy with simvastatin was demonstrated using MRI by Corti et al. However, the effects of different doses of statin on atherosclerotic plaques had not been assessed by MRI. An article published in the March 1st 2005 issue of JACC reports the effects of 5 and 20 mgs of atorvastatin on serum LDL, hs-CRP and atherosclerotic plaques in the abdominal and thoracic aorta.
Two of the authors from this article, Drs Yukihiko Momiyama and Zahi Fayad, share the data and discuss the implications for the practicing cardiologist.
In addition, learn the features of a vulnerable plaque as seen by MRI and the site-specific differences of atherosclerotic plaques.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
Jorge Plutzky, MD
Peter H. Jones, MD
|
| Abstract: |
|
Drs. Jorge Plutzky, Peter H. Jones, and Dolph Hutter discuss the clinical role of statins combined with ezetimibe, niacin, and/or fibrates.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
William B. Kannel, MD
Gregg C. Fonarow, MD
|
| Abstract: |
|
Join this conversation with Drs. William Kannel, Gregg Fonarow, and Dolph Hutter as they review the latest changes in target LDL, highlight factors used in risk assessment, and discuss strategies to achieve lower target levels.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
Nieca Goldberg, MD
Jean C. McSweeney, PhD, RN
|
| Abstract: |
|
Studies have shown that some risk factors for development of heart disease in women may be different from men. Also, clinically these patients may stray from the classical presentation of AMI.
Join Drs. Nieca Goldberg, Jean McSweeney, and Dolph Hutter as they discuss these important distinctions in risk and clinical presentation as they review recent study data.
|
| Watch Program |
|
Back to Top
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
Michael O'Rourke, MD
Thomas Giles, MD
|
| Abstract: |
|
Pulse pressure is defined as the systolic minus the diastolic pressure. This value appears, at least in some epidemiologic studies, to be superior in predictive value to the systolic or diastolic values alone.
Joining this conversation to discuss the relevance of pulse pressure as a predictor of risk for cardiovascular events are Dr Michael O'Rourke, an expert in pulse pressure and cardiovascular disease and Dr Thomas Giles, a hypertension specialist and past president of the American Society of Hypertension.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
George L. Bakris, MD
Aram V. Chobanian, MD
|
| Abstract: |
|
The main aims of the treatment of hypertension are to prevent end-organ damage (EOD) and to avoid consequent lethal complications associated with hypertension. Blood pressure level is a well-known determinant of EOD and achieving BP targets represents the most important determinant of cardiovascular and renal protection. However, it has been suggested that specific classes of antihypertensive drugs may exert additional organ protection beyond their BP control.
Joining this conversation to discuss compelling data on end-organ protection with antihypertensive agents are Dr. Aram Chobanian and Dr George Bakris, both hypertension experts and members of the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7).
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
Haralambos Gavras, MD
Michael A. Weber, MD
|
| Abstract: |
|
The renin-angiotensin system (RAS) has been well-established in playing a key role in regulating blood volume, arterial pressure, and cardiac and vascular function. As renin catalyzes the first and rate-limiting step of the RAS, direct inhibition of renin has long been a therapeutic goal.
Joining this conversation to discuss the current data and potential outlook of renin inhibitors are Dr. Haralambos Gavras and Dr. Michael Weber, both thought leaders in hypertension and cardiovascular disease.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (Moderator)
Jay N. Cohn, MD
John M. Flack, MD, MPH
Michael A. Weber, MD
|
| Abstract: |
|
The renin-angiotensin system (RAS) has been well established in playing a key role in regulating blood volume, arterial pressure, and cardiac and vascular function. Excessive RAS activity increases BP and can lead to end-organ damage. Current classes of RAS-blocking antihypertensive therapies have offered effective treatment for hypertension and many other related cardiovascular disorders, but these agents do not completely inhibit the RAS. Expanding the traditional RAS targets to include the treatment of hypertension underscores a significant need among health care providers involved in the diagnosis and treatment of hypertensive patients.
Joining this conversation to discuss the RAS, its current pharmacologic inhibition, and potential future targets are Dr. Michael Weber and Dr. John Flack, both hypertension specialists, and Dr. Jay Cohn, a prominent clinical trialist specializing in heart failure.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
Lars Lindholm, MD
Franz Messerli, MD
|
| Abstract: |
|
Although beta-blockers have been proven to be effective in secondary prevention of heart disease, a recent meta-analysis published in The Lancet calls into question whether beta-blockers should be used as first-line therapy in the treatment of primary hypertension. Thirteen randomized controlled trials (n=105,951) were included in a meta-analysis comparing treatment with blockers with other antihypertensive drugs. Seven studies (n=27,433) were included in a comparison of blockers and placebo or no treatment.
In the meta-analysis, the relative risk of stroke was found to be 16 percent higher for beta-blockers than for other drugs. When the effect of blockers was compared with that of placebo or no treatment, the relative risk of stroke was reduced by 19 percent for all blockers, roughly half of that expected from previous hypertension trials. The article stated that in comparison with other antihypertensive drugs, the effect of beta-blockers is sub-optimal, with a raised risk of stroke. The authors believe that beta-blockers should not remain first choice in the treatment of primary hypertension and should not be used as reference agent in future randomized controlled trials of hypertension.
Joining this Conversation is one of the authors of the recent Lancet article, Dr. Lars Lindholm, and Dr. Franz Messerli, a well-known hypertension specialist. to help us interpret this data. After reviewing the data from the Lancet article they review other data that shed light on the role of beta-blockers in hypertension and provide their recommendations for first-line agents.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
Michael A. Weber, MD, Professor of Medicine, SUNY Downstate College of Medicine
Richard Blyton Devereux, MD, Professor of Medicine, Weill Medical College of Cornell University
|
| Abstract: |
|
Dr. Adolph Hutter interviews Drs. Richard Devereux and Michael Weber. Both guests, who have recently published on the topic of LV mass, explain how to optimize use of echocardiography to obtain accurate LV measurements. Watch as they review the literature and provide practical suggestions for utilizing LV mass as an indicator of severity of disease and as an efficacy measurement.
All the major anti-hypertensive classes are highlighted for their effects. Find out which ones cause regression, which cause worsening, and which ones have no effect on LV mass.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
Stevo Julius, MD Professor of Internal Medicine and Physiology
Carl Pepine, MD Professor of Medicine
|
| Abstract: |
|
Large randomized clinical trials have shown a difference in the emergence of new diabetes among the main CV drug classes.
Drs. Stevo Julius, Carl Pepine, and Dolph Hutter review the data relating to the effects of commonly used antihypertensives on diabetes onset.
The content of this Conversation is essential when considering long-term drug therapy for hypertension and even heart failure.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
George L. Bakris, MD
Keith C. Ferdinand, MD
|
| Abstract: |
|
The GEMINI Trial (Glycemic Effects in Diabetes Mellitus: Carvedilol - Metoprolol Comparison in Hypertensives) was a randomized, double-blind, parallel-group trial designed to compare the effects of ß-blockers with different pharmacologic profiles on glycemic and metabolic control in participants with Type II diabetes and hypertension receiving renin-angiotensin system (RAS) blockade.
Join Drs. George Bakris, Keith Ferdinand, and Dolph Hutter as they discuss the late-breaking trial data released at the 2004 American Heart Association (AHA) Scientific Sessions and its bearing on clinical practice.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
Jerome D. Cohen, MD
Elijah Saunders, MD
|
| Abstract: |
|
Drs. Elijah Saunders, Jerome Cohen, and Dolph Hutter discuss the major findings of the AADVANCE trial and its relevance to treating African-Americans with hypertension, both with and without concomitant diabetes and/or renal dysfunction.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
John H. Laragh, MD
Barry J. Materson, MD
George L. Bakris, MD
|
| Abstract: |
| Join Drs. John Laragh, George Bakris, Barry Materson, and Dolph Hutter as they discuss how best to interpret the recommendations from the JNC VII. Their clinical experience and data from trials guide the views expressed on the appropriateness of thiazide diuretics as first-line therapy and effective blood pressure target levels.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
John Laragh, MD
William White, MD
|
| Abstract: |
|
Join Drs. John Laragh, William White, and Dolph Hutter as they discuss the clinical relevance of the VALUE trial data published in The Lancet.
Hear reasons why the effects of the amlodipine-based regimen were more pronounced in reducing blood pressure early. And how these unequal reductions in blood pressure might account for differences between the groups in cause-specific outcomes. The findings emphasise the importance of controlling blood-pressure early in hypertensive patients at high cardiovascular risk.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
Robert A. Phillips, MD, PhD
Henry R. Black, MD
|
| Abstract: |
|
The cardiovascular benefits of reducing blood pressure have been well proven, but there is still uncertainty about the comparative effects of different blood-pressure-lowering agents.
With recent anti-hypertensive trials focusing on the benefits of therapies beyond blood pressure control, the Conversation will help the practicing cardiologist interpret current data for clinical application.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
Richard Blyton Devereux, MD
John M. Flack, MD, MPH
|
| Abstract: |
|
There are many options other than beta-blockers for patients with hypertension, including ACE inhibitors, angiotensin receptor blockers, calcium channel blockers and/or diuretics.
Using recent INVEST trial data as a springboard, Drs. Hutter, Devereux and Flack discuss alternatives for treating hypertensive patients with concomitant conditions aggravated by beta blockade.
Take part in this Conversation if you would like to hear the clinically relevant points from the INVEST trial and guidance on choosing alternatives to beta-blocker therapy for your patients.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
Howard S. Weintraub, MD
Matthew R. Weir, MD
|
| Abstract: |
|
Research shows that following a myocardial infarction (MI), treatment with angiotensin converting enzyme (ACE) inhibitors reduces mortality and morbidity in patients with left ventricular dysfunction (LVD). However, long-term benefits remain unknown. The TRACE trial started in 1990 and ended in 1994. After a 10-12 year follow up, the long-term effects of the ACE inhibitor trandolapril were recently presented.
Listen to this conversation for a summary of TRACE trial long-term data, and most importantly, guidance from medical leaders regarding the implications for clinical practice.
|
| Watch Program |
|
| Participant: |
|
Thomas G. Pickering, MD, Assistant Professor of Medicine, Columbia University College of Physicians and Surgeons
|
| Abstract: |
|
Utilizing the ALLHAT trial, this Conversation covers the importance of understanding cardiovascular endpoints in clinical trials, highlighting the shortcomings associated with inappropriately weighing conclusions drawn from primary and secondary endpoints and cost outcomes.
|
| Watch Program |
|
| Participants: |
Peter Kowey, MD, Professor of Medicine, Jefferson Medical College
Franz H. Messerli, MD, Clinical Professor of Medicine, Tulane University Medical School
|
| Abstract: |
|
The efficacy of antihypertensive agents for hypertension coexisting with coronary artery disease has been examined only as subgroup analyses of larger trials. Join in a discussion of recent studies that have examined outcomes in patients with HTN and CAD treated with a calcium antagonist or a non-calcium antagonist strategy.
|
| Watch Program |
|
Back to Top
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
Zahi A. Fayad, PhD, Associate Professor of Radiology and Medicine, Mount Sinai School of Medicine
Yukihiko Momiyama, MD, Assistant Professor, First Department of Internal Medicine, National Defense Medical College, Japan
|
| Abstract: |
|
Thoracic aortic plaque regression after lipid-lowering therapy with simvastatin was demonstrated using MRI by Corti et al. However, the effects of different doses of statin on atherosclerotic plaques had not been assessed by MRI. An article published in the March 1st 2005 issue of JACC reports the effects of 5 and 20 mgs of atorvastatin on serum LDL, hs-CRP and atherosclerotic plaques in the abdominal and thoracic aorta.
Two of the authors from this article, Drs Yukihiko Momiyama and Zahi Fayad, share the data and discuss the implications for the practicing cardiologist.
In addition, learn the features of a vulnerable plaque as seen by MRI and the site-specific differences of atherosclerotic plaques.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
Michael A. Weber, MD, Professor of Medicine, SUNY Downstate College of Medicine
Richard Blyton Devereux, MD, Professor of Medicine, Weill Medical College of Cornell University
|
| Abstract: |
|
Dr. Adolph Hutter interviews Drs. Richard Devereux and Michael Weber. Both guests, who have recently published on the topic of LV mass, explain how to optimize use of echocardiography to obtain accurate LV measurements. Watch as they review the literature and provide practical suggestions for utilizing LV mass as an indicator of severity of disease and as an efficacy measurement.
All the major anti-hypertensive classes are highlighted for their effects. Find out which ones cause regression, which cause worsening, and which ones have no effect on LV mass.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
Malissa J. Wood, MD
|
| Abstract: |
|
Join this discussion on how to accurately measure left atrial volume and the adverse outcomes associated with enlargement.
|
| Watch Program |
|
Back to Top
| Participants: |
Adolph M. Hutter Jr, MD, MACC, FAHA, FESC (moderator)
Steven E. Nissen, MD
Benjamin M. Scirica, MD
Marc Pfeffer, MD, PhD
|
| Abstract: |
|
Several studies have reported improvement in overall outcomes in HF patients treated with statins. The possible mechanisms of benefit, other than treatment of coronary disease that may have been unrecognized, are not known.
Joining this conversation to discuss the benefits and possible mechanisms of statin use in patients with heart failure are Dr Steven Nissen, specialist in atherosclerosis and current President of the ACC, and Dr Benjamin Scirica and Dr Marc Pfeffer, both clinical trialists in heart failure.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
Marvin A. Konstam, MD
Lynne W. Stevenson, MD
Marc J. Semigran, MD
|
| Abstract: |
|
According to the ACC/AHA guideline for the diagnosis and management of chronic heart failure, stage C includes patients with structural heart disease and symptomatic heart failure.
Joining this conversation to discuss the current treatment options for patients who have stage C heart failure are Dr. Lynne Stevenson, Dr. Marvin Konstam, and Dr. Marc Semigran, all clinical cardiologists and experts in the treatment of heart failure.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
Christopher O'Donnell, MD
Keith C. Ferdinand, MD
|
| Abstract: |
|
Healthcare providers often rely on personal experience and clinical guidelines when determining the appropriate therapy for a patient. These guidelines often are based on "mega trials" which study a large heterogeneous population and make the assumption that everyone responds the same or "one drug fits all".
Joining this conversation to discuss the challenges to understanding racial/ethnic differences in cardiovascular risk factors and treatment outcomes are Dr Christopher O'Donnell, a specialist in genetic epidemiology and subclinical cardiovascular disease and Dr Keith Ferdinand, a leading clinical trialist and author in cardiovascular disease in African American patients.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
James L. Januzzi , MD
Alan S. Maisel, MD
Marc A. Silver, MD
|
| Abstract: |
|
Elevated plasma brain natriuretic (BNP) concentrations correlate with the stretching of the ventricles due to increased cardiac filling pressures. Therefore, increased BNP has been proposed as a marker for ventricular dysfunction, an aid to identify the cause of cardiac dyspnea, an end point to assess the effect of heart failure therapy and a prognostic indicator in heart failure.
Drs. Alan S. Maisel, James L .Januzzi and Marc A. Silver join Dr. Adolph Hutter to share their expertise on BNP.
Join this Conversation to optimally use BNP in your clinical practice. Learn the difference between BNP and N-terminal pro-BNP, how to interpret BNP results for heart failure and acute coronary syndromes, and how to use BNP as a prognostic marker.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
Robert M. Califf, MD
Jay N. Cohn, MD
|
| Abstract: |
|
Listen to this Conversation with two well-known heart failure specialists, Drs. Robert M. Califf and Jay N. Cohn, as they discuss methods to identify and manage individuals in Stages A and B pre-HF.
The implications of the guidelines are provided from various perspectives: the practitioner, the nation, and globally. The discussants also focus on past and future trials that have provided or will provide a greater understanding of individuals with Stage A or B pre-HF.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
Jay N. Cohn, MD
Scott D. Solomon, MD
|
| Abstract: |
|
The risk of sudden death from cardiac causes is increased among survivors of acute myocardial infarction with reduced left ventricular systolic function. The VALIANT (VALsartan In Acute myocardial iNfarcTion) trial assessed the risk and time course of sudden death in high-risk patients after myocardial infarction. It is the largest survival study with an angiotensin II receptor blocker (ARB) ever conducted in patients with post-MI.
Drs. Jay Cohn, Scott Solomon, and Dolph Hutter analyze both past and present data from this trial and provide a review of other relevant trials to guide the practicing cardiologist on how to clinically interpret the data.
Join this Conversation if you would like to learn more about the appropriate use of ACE inhibitors and ARBs in patients with early LVD and HF.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
Michael Bristow, MD, PhD, Professor of Medicine, University of Colorado Health Sciences Center
Marco Metra, MD, Associate Professor of Cardiology,
University of Brescia
Karl Swedberg, MD, Professor of Medicine, Östra Göteborg University
|
| Abstract: |
|
This Conversation with Drs. Karl Swedberg, Michael Bristow, and Marco Metra utilizes new secondary analysis data from the COMET trial presented at the 2005 American College of Cardiology Annual Meeting to further discuss the distinctions between carvedilol and metoprolol.
Learn why metoprolol tartrate was used at a dose of 50 mg bid and its importance when interpreting data from the COMET trial. These heart failure specialists systematically review comparison data on myocardial and metabolic effects.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
Keith C. Ferdinand, MD
|
| Abstract: |
|
Heart failure affects approximately five million Americans. African-Americans suffer a disproportionate incidence of heart failure, develop the condition earlier, and die from the disease at an earlier age. The A-HeFT (African American Heart Failure) Trial is the first study conducted in an all African-American heart failure population.
Results from the A-HeFT were presented at the 2004 American Heart Association's Late-Breaking Scientific Sessions and published in the New England Journal of Medicine (NEJM).
Join as Dr. Keith Ferdinand, an investigator from the trial and an author of the NEJM article briefly summarizes the major findings and clinical conclusions from A-HeFT.
|
| Watch Program |
|
| Participants: |
Adolph M. Hutter, Jr., MD, MACC, FAHA, FESC (moderator)
Michael M. Givertz, MD
Betram Pitt, MD
James Udelson, MD
|
| Abstract: |
|
Join this Conversation on how to best utilize drugs found in the practicing cardiologists heart failure armamentarium.
|
| Watch Program |
|
| |
